Ilixadencel

Press Release Stockholm, Sweden, November 7, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present preclinical data demonstrating immune priming synergies between the intratumoral primer ilixadencel and avelumab, an immune checkpoint inhibitor approved for multiple solid tumor indications, at the SITC 2024 conference. Mendus will present preclinical data demonstrating that ilixadencel and avelumab act synergistically in intratumoral priming of the immune system during the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC), held November 6-10, 2024 (SITC 2024). Addition of avelumab leads to stronger natural killer cell activation by ilixadencel, enhances production of proinflammatory cytokines and chemokines in ilixadencel-stimulated peripheral blood mononuclear cells and leads to improved maturation of bystander dendritic cells. The presented data indicate that ilixadencel and avelumab act synergistically to promote a pro-inflammatory tumor microenvironment required for effective anti-tumor immune responses. The data will be presented by Mendus’ Director Research Dr Satwinder Kaur Singh on Friday, November 8, at 12.15 CST. Abstracts are available online on the SITC website Titles and Publications – SITC 2024 . Please find below the details of the abstract to be presented by Mendus: Abstract Number 761; Title: The intratumoral immune primer ilixadencel acts synergistically with the anti-PD-L1 antibody avelumab; Date: Friday, November 8, 2024; Presentation Time: 12.15-1.45 pm CST; Location poster session: Exhibit Halls A B, George R. Brown Convention Center, Houston, Texas, USA In July, Mendus announced a collaboration with Institut Bergonié, a leading cancer research centre based in Bordeaux, France, to study ilixadencel in soft tissue sarcomas as part of the REGOMUNE trial, a multicenter, prospective open-labeled phase 1/2 trial combining regorafenib, a tyrosine kinase inhibitor (TKI), and avelumab, an immune checkpoint inhibitor, in solid tumors. Mendus will support the REGOMUNE trial by supplying ilixadencel as study drug to treat up to 43 soft tissue sarcoma (STS) patients. Ilixadencel is an off-the-shelf intratumoral immune primer consisting of pro-inflammatory monocyte-derived dendritic cells (DCs) from allogeneic healthy donor material. Upon administration, ilixadencel promotes a local pro-inflammatory environment, activation of NK cells and cross-presentation of tumor antigens by recruited and activated endogenous DCs in the tumor microenvironment. In clinical trials, ilixadencel has demonstrated promising signs of efficacy in hard-to-treat solid tumors and was shown to be safe in combination with tyrosine kinase inhibitors and immune checkpoint inhibitors. The data presented at SITC support clinical evaluation of ilixadencel in combination with avelumab, the immune checkpoint inhibitor used in the REGOMUNE trial. For more information, please contact: Erik MantingChief Executive OfficerE-mail: ir@mendus.com About Mendus AB (publ) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ Attachments241107 Mendus SITC 2024 ENG

Press Release Stockholm, Sweden, October 8, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry and investor conferences in the period October-November 2024: LSX Nordic conferenceCopenhagen, Denmark, October 8-9 Mendus CEO Erik Manting will hold a company Showcase presentation on October 9, 11.00 CET. Dr Manting will also participate in a panel discussion titled “ATMPs and a New Paradigm Shift for Patients: Initiatives and Ambitions in the Nordics” on October 9, 14.50 CET. The panel focuses on how new advanced therapies (ATMPs) offer life-changing potential for many patients who battle with serious rare diseases and cancers. Mendus has entered into an ATMP manufacturing alliance with NorthX Biologics, to enable large-scale manufacturing of its lead product, vididencel. Biotech, Healthtech & Medtech Investment | LSX Nordic Congress (informaconnect.com) CONDOR SymposiumBordeaux, France, October 10-11 Mendus CMO Jeroen Rovers will participate in the annual symposium of the Precision Medicine and Immunotherapy of Sarcoma (CONDOR) program, held at Institut Bergonié, Bordeaux, France. Together with Institut Bergonié, Mendus is preparing to study the intratumoral primer ilixadencel in combination with regorafenib and avelumab as a novel treatment for soft tissue sarcoma as part of the REGOMUNE trial. See our July 23 press release of for more background Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas – Mendus. For more information on the CONDOR program, please visit HOME – CONDOR PROGRAM – Therapeutic Management of STS EVENTS & MEETINGS – CONDOR PROGRAM – Management of STS BioEuropeStockholm, Sweden, November 4-6 Mendus CEO Erik Manting will participate for investor and industry meetings. BIO-Europe | Meet dealmakers from biotech, pharma and finance (informaconnect.com) SITC 2024Houston, Texas, USA, November 6-10 On November 8, Mendus will present preclinical data supporting the combination of its intratumoral primer ilixadencel with the immune checkpoint inhibitor avelumab at the 39th annual meeting of the Society for Immunotherapy of Cancer (SITC). SITC abstract titles are available via Titles and Publications – SITC 2024 (sitcancer.org), abstract number is 761. Together with Institut Bergonié, Mendus is preparing study ilixadencel in combination with avelumab and the tyrosine kinase inhibitor regorafenib in soft tissue sarcoma, as part of the REGOMUNE trial. Home – SITC 2024 (sitcancer.org) ALLG Scientific MeetingMelbourne, Australia, November 12-15 Mendus CMO Jeroen Rovers will participate in the biannual investigator meeting organized by the Australasian Leukaemia and Lymphoma Group (ALLG). Together with ALLG, Mendus will study its lead program vididencel as a novel maintenance therapy for acute myeloid leukemia (AML) in combination with oral azacitidine (aza) in the AMLM22-CADENCE trial. Mendus and ALLG are in the process of opening up to 9 clinical centres in 2024Q4 to support the first stage of the trial, which comprises 40 patients to study the safety of the vididencel + oral aza combination. This stage will be followed by another 100 patients to study efficacy of the combination versus oral aza, currently the only approved AML maintenance drug. November 2024 Scientific Meeting | The Australasian Leukaemia and Lymphoma Group (allg.org.au) Jefferies Healthcare ConferenceLondon, UK, November 19-21 Mendus CEO Erik Manting will participate for investor and industry meetings. Jefferies Global Healthcare Conference 2024 | Jefferies.com For more information, please contact: Erik MantingChief Executive OfficerE-mail: ir@mendus.com About Mendus AB (publ) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. https://www.mendus.com/ Attachments241008 Mendus Conferences OctNov ENG